This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About ATTR-CMAbout
ATTR-CM
Disease ImpactWhen to Rule Out ATTR-CMDiagnosing ATTR-CM
About VYNDAMAXAbout
VYNDAMAX
Mortality and Hospitalization6MWT/KCCQ-OS5-year DataHow VYNDAMAX WorksSafety Profile Study Design
DosingAccess & SupportAccess & SupportAccessing VYNDAMAXPaying for VYNDAMAXResourcesResourcesEventsMaterialsVideos
Prescribing InformationPatient InformationIndication Patient Site
Paying for VYNDAMAX
Medicare

MEDICARE CHANGES FOR 2025: Medicare patients will pay no more than $2,000 total for all their Part D medications, including VYNDAMAX, for the full year of 2025.

Nationally, more than 94% of Medicare Part D patients have access to VYNDAMAX after meeting applicable PA criteria.

Medicare patients will have the option to enroll in the Medicare Prescription Payment Plan to spread their drug costs over the course of the year.

Commercial Insurance

Nationally, 90% of commercially insured patients have access to VYNDAMAX after meeting applicable PA criteria

Commercial Co-Pay Assistance

Eligible commercially insured patients may pay as little as $0 per month through the VYNDAMAX Co-Pay Savings Program.

Get the card now Loading
VYNDAMAX CO-PAY SAVINGS PROGRAM TERMS AND CONDITIONS

By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below: 

  • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). 
  • Patient must have private insurance. Offer is not valid for cash-paying patients. 
  • Patients are responsible for as little as a $0 monthly copayment based upon program utilization. 
  • You will receive a maximum benefit of $10,000–$60,000 per calendar year, which is defined by the date of enrollment through December 31st of the enrollment year. After a maximum is reached, you will be responsible for paying the remaining monthly out-of-pocket costs. 
  • This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. 
  • You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. 
  • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards. 
  • You must be 18 years of age or older to redeem the co-pay card. 
  • This co-pay card is not valid where prohibited by law. 
  • The benefit under this co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either. 
  • This co-pay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs). 
  • Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the co-pay card program. 
  • This co-pay card will be accepted only at participating pharmacies. 
  • This co-pay card is not health insurance. 
  • Offer good only in the US and US Territories. 
  • This co-pay card is limited to 1 per person during this offering period and is not transferable. 
  • A co-pay card may not be redeemed more than once per 24 days per patient.
  • No other purchase is necessary. 
  • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this offer without notice. 
  • Offer expires 12/31/25.
To contact VyndaLink, call 1-888-222-8475, Monday-Friday 9 AM-6 PM ET
Medicare Extra Help/Low-Income Subsidy (LIS)
Medicare patients eligible for the Low-Income Subsidy (LIS) program have access to VYNDAMAX for a co-pay of ≤$11.20 per prescription after meeting applicable PA criteria.

Extra help with Medicare Part D costs is available to qualifying patients. Learn more about the Extra Help Program at Medicare.gov

VyndaLink* can help connect patients on Medicare/government insurance, commercial insurance, or no insurance with financial assistance resources

Connect eligible patients with financial assistance resources

Conduct a benefits verification to determine your patient’s coverage for VYNDAMAX and VYNDAQEL® (tafamidis meglumine), including out-of-pocket costs

Identify payer requirements for VYNDAMAX and provide information about the prior authorization process as needed

Identify specialty pharmacy options based on your patient’s insurance coverage. VYNDAMAX is available through multiple specialty pharmacies

Title
Call VyndaLink at 1-888-222-8475 Monday-Friday, 9 AM-6 PM ET or
go to www.VyndaLink.com
Next: Learn about Accessing VYNDAMAX ContinueLoadingSee www.VyndaLinkPortal.com for details.*The same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL.†Please note where a PA is required, the physician must submit required information directly to the patient’s insurer.PA=prior authorization.
Access & Support

Pfizer Field Access Specialists (FAS) can help providers understand the VYNDAMAX access journey 

Ask your Pfizer representative to connect you with your local FAS

Pfizer Patient Access Coordinators (PACs) can help your patients during their treatment journey

All patients with a valid VYNDAMAX prescription are eligible to opt in

Request PAC Support Loading
VyndaLink.com has more information about support services for you and your patients View VyndaLinkLoading
Access resources for you and your patient Explore resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-VDM-USA-1962
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-VDM-USA-0908
INDICATION AND LIMITATIONS OF USE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Please see Full Prescribing Information including Patient Information.
Important Safety InformationAdverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.
IndicationVYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.